中央實驗室市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Central Lab Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月16日 | 出版商:

Global Market Insights Inc. | 英文 110 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023 年，全球中心實驗室市場價值約為 31 億美元。這一成長主要得益於對外包測試服務的日益重視以及研發投資的大幅增加。

出於對成本效率、高品質結果和專業測試能力的追求，組織擴大轉向外包測試服務。美國食品藥物管理局(FDA) 報告稱，2022 年利用外包中心實驗室服務的臨床試驗激增25%，較2019 年顯著增加。確保準確、快速的測試，推動市場成長。

技術進步正在重塑實驗室服務的格局。下一代定序 (NGS)、自動化實驗室系統、人工智慧、機器學習、即時檢測突破和複雜的生物感測器等創新正在提高精度和效率，同時擴大所提供的服務範圍。這些發展對於定義產業發展軌跡至關重要。

中央實驗室市場根據服務、應用、最終用途和區域進行細分。

生物標記服務領域在市場上佔據主導地位，2023 年收入為 9.345 億美元。這些生物標記對於識別特定疾病途徑和預測患者對治療的反應至關重要，這使得它們對於開發個人化治療至關重要。這一趨勢極大地推動了對生物標記服務的需求。製藥和生物技術產業依靠生物標記來提高藥物開發的效率和效果，進一步拉動對生物標記服務的需求。

中央實驗室市場根據腫瘤學、神經學、心臟病學、傳染病和其他應用的應用進行分類。腫瘤學領域預計將主導中央實驗室產業，預計到 2032 年收入將達到 16 億美元。中心實驗室對於提供癌症專業檢測和診斷服務至關重要，包括基因分析、生物標記分析和組織病理學，以支援腫瘤學研究和臨床實踐。液體活體組織切片、新一代定序 (NGS) 和先進成像等診斷技術的進步使得精確、早期檢測和個人化治療成為可能，從而推動了對腫瘤學專業實驗室服務的需求。

到 2023 年，北美中心實驗室市場的收入將達到 11 億美元，預計在分析時間內將大幅成長。北美對個人化醫療的日益關注增加了對先進診斷服務和生物標記的需求，從而推動了整個北美中心實驗室的需求。癌症和糖尿病等慢性病發病率的上升需要更全面的測試和研究，從而推動了北美中心實驗室產業的成長。

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

A.P. Moller Holding A/S
ACM Global Laboratories
BioAgilytix Labs
Cerba Research
Cirion Biopharma Research Inc.
Covance Inc.
Eurofins Scientific
Frontage Laboratories
ICON Central Laboratories
LabConnect
Laboratory Corporation of America Holding
Lambda Therapeutics Research Ltd
Medpace, Inc.
Parexel International Corporation
Quest Diagnostics
Versiti

簡介目錄

Product Code: 10831

The Global Central Lab Market was valued at approximately USD 3.1 billion in 2023. Projections indicate it will grow to around USD 5.1 billion by 2032, achieving a CAGR of 5.8% during the forecast period. This growth is primarily fueled by a rising emphasis on outsourcing testing services and a significant uptick in research and development investments.

Organizations are increasingly turning to outsourced testing services, motivated by the pursuit of cost efficiency, high-quality results, and specialized testing capabilities. The U.S. Food and Drug Administration (FDA) reported a 25% surge in clinical trials leveraging outsourced central laboratory services in 2022, a marked increase from 2019. By outsourcing, organizations can focus on their primary activities, while central labs ensure accurate and swift testing, propelling the market's growth.

Technological advancements are reshaping the landscape of lab services. Innovations such as next-generation sequencing (NGS), automated laboratory systems, artificial intelligence, machine learning, point-of-care testing breakthroughs, and sophisticated biosensors are enhancing precision and efficiency while broadening the range of services offered. These developments are pivotal in defining the industry's trajectory.

The central lab market is segmented based on services, application, end-use, and region.

The biomarker services segment dominated the market with a revenue of USD 934.5 million in 2023. Precision medicine, which customizes treatments based on individual genetic, environmental, and lifestyle factors, heavily relies on biomarkers. These biomarkers are essential for identifying specific disease pathways and predicting patient responses to therapies, making them critical for developing personalized treatments. This trend significantly drives the demand for biomarker services. The pharmaceutical and biotech industries rely on biomarkers to enhance the efficiency and effectiveness of drug development, further boosting the demand for biomarker services.

The central lab market is categorized based on applications into oncology, neurology, cardiology, infectious diseases, and other applications. The oncology segment is anticipated to dominate the central lab industry, with a projected revenue of USD 1.6 billion by 2032. The high prevalence of cancer drives the demand for extensive cancer research, diagnostics, and treatment monitoring. Central labs are crucial in providing specialized testing and diagnostic services for cancer, including genetic profiling, biomarker analysis, and histopathology, to support oncology research and clinical practice. Advancements in diagnostics, such as liquid biopsy, next-generation sequencing (NGS), and advanced imaging, enable precise, early detection and personalized treatment, driving the need for specialized lab services in oncology.

In 2023, North America central lab market accounted for USD 1.1 billion in revenue and is predicted to witness substantial growth over the analysis timeline. The increasing focus on personalized medicine in North America boosts demand for advanced diagnostic services and biomarkers, driving the demand for central labs across North America. The rising incidence of chronic diseases such as cancer and diabetes necessitate more comprehensive testing and research, fueling the growth of central lab industry in North America.

Chapter 1 Methodology and Scope

1.1 Market scope and definition
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing emphasis on outsourcing of testing services
  - 3.2.1.2 Technological advancements in testing equipment
  - 3.2.1.3 Extensive growth in research and development investments
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Stringent government regulations and compliance
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Porter's analysis
3.7 PESTEL analysis
3.8 Future market trends

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Services, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Genetic services
5.3 Biomarker services
5.4 Microbiology services
5.5 Anatomic pathology/histology
5.6 Specimen management and storage
5.7 Other services

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Oncology
6.3 Neurology
6.4 Cardiology
6.5 Infectious diseases
6.6 Other applications

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Pharmaceutical and biotechnology companies
7.3 Academic and research institutes
7.4 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 Saudi Arabia
- 8.6.2 South Africa
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa